Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) versus Aridis Pharmaceuticals (NASDAQ:ARDS)

Insider & Institutional Ownership

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares ASLAN Pharmaceuticals and Aridis Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Aridis Pharmaceuticals	N/A	N/A	N/A

Risk and Volatility

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 47.59, meaning that its share price is 4,659% more volatile than the S&P 500.

Earnings and Valuation

This table compares ASLAN Pharmaceuticals and Aridis Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12.00 million	0.10	-$44.22 million	($21.92)	-0.03
Aridis Pharmaceuticals	N/A	N/A	-$30.37 million	$0.31	0.00

Aridis Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Aridis Pharmaceuticals beats ASLAN Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.